Letter from the President - Kris De Boeck

Dear Friends,

I hope you had a good start of the year.

2015 was another very busy year for the European Cystic Fibrosis Society, with not only the Basic Science Conference in Albufeira and the Annual conference in Brussels, but a number of special projects and Working Group meetings were held and some selected updates are given below.

Later in this newsletter, you will read some news about recent initiatives which comprise the initiation of ECFS Special Interest Groups, a report from the first beneficiary of an ECFS Short-Term Fellowship and a new membership offer for Allied Health Professionals, PhD Students and Post Docs.

There will be Board elections in 2016 with both Margarida Amaral and Tania Pressler ending their terms in office. I would like to encourage you all to consider your own nomination or to nominate an ECFS member you believe would benefit the ECFS community by being actively engaged in the Board. Please consider how important these elections are for the future of the Society. Further information about the elections is included later in the Newsletter.

Planning for the 2016 Conference is well underway with all necessary information available on the website. I would like to thank all those who have submitted abstracts and all the speakers who have accepted to contribute to the conference. We have excellent programmes planned and we look forward to your participation.

We have a lot to do over the coming months and I hope you will join us for some of these activities.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in cystic Fibrosis contained in this Newsletter.
Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,
Kris De Boeck, ECFS President

2. ECFS Award - Call for Nominations

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis. The winner of the award will be invited to present a lecture at the Opening Plenary on 8 June 2016 of the annual conference in Basel. You are cordially invited to nominate a candidate for this award. The deadline for proposals is March 1, 2016. Please mail your proposal, accompanied by a detailed motivation and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu).

3. Gerd Döring Award - Call for Nominations

The Gerd Döring Award is a new initiative of the European Cystic Fibrosis Society and will be given annually to honour an exceptional early career young European scientist. The Award, a monetary donation of 5,000 euro to support research, will be presented at the Opening Plenary of the annual ECFS conference in Brussels. The award will be judged primarily (80%) on a paper published in the previous 3 calendar years (2013-2015) which has made a significant impact on the understanding or treatment of Cystic Fibrosis. Personal motivation and CV will make a 20% contribution to the scoring. The award is open to PhD students and post-doctoral researchers with up to a maximum of four years’ academic research experience following the completion of their PhD, or be of equivalent professional standing at the date of publication of the paper. We encourage mentors, supervisors and co-workers of today's most exceptional early career European scientists to send in nominations for this competition. Self-nomination is also encouraged. The deadline for proposals is March 1, 2016. Please mail your proposal, accompanied by a detailed motivation, a PDF of the nominated paper and curriculum vitae of the candidate to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu).

4. ECFS Board Elections - call for nominations

The ECFS cordially invites nominations for the following Board positions. In June 2016, Margarida Amaral finishes her first term on the Board (and could stand again) and Tania Pressler is stepping down from the Board after completing two terms. Job Descriptions and person specifics are available for Board members.

Board Member’s Job Description.
Nominations should be sent to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu) by 15 March 2016 together with a motivational statement, confirmation that the candidate has agreed to the nomination, and a curriculum vitae. All nominated candidates must be current members of the ECFS. Information about the nominated candidates will be sent to the membership in April for an online vote prior to the Annual General Meeting in June where the results will be announced.
5. ECFS Meetings in Prague

The ECFS Clinical Trials Network and ECFS Patient Registry Steering Committees met on 27-29 January in Prague for their annual winter meetings. We especially welcomed the new CTN members. This was an excellent opportunity to meet across ECFS projects, discuss common subjects and find new and even better opportunities for cooperation.

CTN Steering Committee meeting Prague, January 27-29

Investigators from 38 of the 43 CTN sites were able to join this yearly winter meeting. Patient organizations from Belgium, Germany, Italy, Luxemburg, Switzerland, The Netherlands and UK were also represented. As in previous years, Dr. George Retsch-Bogart traveled to Europe and attended as CFF-TDN representative.

Investigators of the new sites that have recently joined the CTN attended a one hour introduction and training session to get familiar with the network’s code of conduct, available tools and information and the online Trial Management System.

The steering committee meeting started with looking back at 2015. The past year was extremely busy for the protocol review groups and for conducting feasibility checks for new studies at the sites. This means that the network is expecting a significant increase in patients to be enrolled in the upcoming trials.

Dr. Tim Lee provided some examples of successful advocacy by the network and an update on the action items related to the business plan. Options on starting an investigator initiated trial based on patient priorities were discussed. A new committee will look into the setup of a Young Persons Advisory Group.

Updates were provided by the different committees (protocol review, training, DSMB, standardization). Some specific projects and networking activities were also presented.

A significant part of the meeting was devoted to topics related to site quality management. The yearly report on site quality assessment was presented and strategies to cope with the pipeline of upcoming trials were discussed.

Additional meetings were organized between the Executive Committees of the ECFS-CTN and the ECFS Patient Registry and with the patient organizations funding research. As always the ECFS winter meeting has been an excellent opportunity for all parties to meet each other, to have fruitful discussions and to work on new initiatives.

Patient Registry Executive and Steering Committees meetings

The country representatives and staff of the ECFS Patient Registry met in Prague to discuss current developments and future plans in the Executive Committee and Steering Group meetings. In a productive and animated atmosphere the various projects defined in the business plan were discussed: the publication of the Annual Report 2013 in February, with demographic and clinical data of over 39,000 consenting CF patients from 27 countries; the publication of the Annual Report 2014 in September this year; the progress of an at-a-glance report with a compilation of the information from the Annual Report to bring data closer to patients; and the development of a benchmarking module in ECFSTracker, an important tool to improve CF care. The registry continues to expand; in 2015 Turkey joined the registry bringing the number of participating countries to 29.
6. ECFS Special Interest Groups

The ECFS is pleased to announce the initiation of three ECFS Special Interest Groups dedicated to Nursing, Pharmacy and Psychosocial issues:
- The European Cystic Fibrosis Pharmacy Group (ECFPG)
- The ECFS Psychosocial Special Interest Group (EPSIG) - CF
- The ECFS Nurse Specialist Interest Group (ECFS NSiG)

ECFS Special Interest Groups Membership is open to all. Should you be interested in joining one of these groups, please send a note to Christine Dubois, Christine.dubois@ecfs.eu.

The Special Interest Groups will hold their meetings at the ECFS conference in Basel and more information will soon be available on the ECFS website.

7. Clinical training fellowships

The ECFS has partnered with the course ‘Managing the care of children and adults with cystic fibrosis’ held twice a year in London, UK or on-line, www.cfcourse.co.uk, to offer clinical placements to members of the CF multidisciplinary team.

Sponsorship includes free attendance at the course in London or participation in the on-line course, followed by a two week placement at the Royal Brompton Hospital (paediatric or adult departments). Travel and accommodation will be covered.

The course is held twice a year in March and September; the on-line course can be done at any time. www.cfcourse.co.uk

If you are interested please contact the ECFS, info@ecfs.eu

8. Letter from the first recipient of an ECFS Short Term Clinical Fellowship

To the ECFS and members of the Royal Brompton Hospital CF Unit,

Last November, I was very fortunate to have the opportunity to participate in the ECFS short-term clinical fellowship at the Royal Brompton Hospital Cystic Fibrosis (CF) Unit in London. As a junior CF physician in Sydney, Australia, it was a wonderful chance to improve my own knowledge and clinical skills in CF management as well as take home constructive and practical ideas to help enhance our own program.

My two week fellowship was well structured with time allocated for adult and paediatric clinics, annual reviews, inpatient ward rounds and personalised sessions with the physiotherapy, dietetics, nurse specialist, palliative care and psychology team members. The schedule also allowed for additional time to incorporate many questions and topics that I was hoping to cover during my visit! It included spending half a day at the “Difficult CF Diagnosis” clinic where I learnt about the utility of nasal potential difference in clinical practice, and an afternoon with the clinical trials coordinators and research fellow. Time spent at diabetic ward rounds and at one-on-one sessions with expert clinicians was extremely helpful and comprehensive.

I also attended several meetings including Journal Club and Respiratory Grand Rounds but my absolute favourite was the CF Multidisciplinary meeting. There may be a few team members rolling their eyes or expressing some level of shock at this revelation as the meeting is rather lengthy. It was however run very smoothly as it highlighted strengths of every team member and allowed for time to review all inpatients and active outpatients. I also had my first ever bacon sandwich with brown sauce here, which arrived right at the middle of the meeting, like a much anticipated intermission or halftime show at a major sporting event.
The clinical fellowship also included access to the “Managing the care of children and adults with CF” online course, which had useful detail and reviewed a broad range of topics, including basic CF related concepts as well as evidence based multidisciplinary clinical practice delivered by experts in the field. This was helpful pre-reading prior to my clinical placement.

Suffice to say, I thoroughly enjoyed the clinical fellowship. Hopefully, I am also a better CF physician for it. I felt very at home at the CF Unit as everyone clearly made an effort to make me feel welcome and part of the team. I wanted to especially thank Su Madge, the consultant nurse who organized the placement, for her enthusiasm and kindness, Liz Holder, Nick Simmonds, the acting lead and his team, Christine Dubois and the ECFS for this wonderful opportunity.

Sincerely,

Sheila Sivam
Locum CF Physician
Royal Prince Alfred Hospital
Sydney, Australia.

9. ECFS Special membership offer for Allied Health Professionals, PhD students and Post Docs

This year a new membership offer was introduced:
Allied Health Professional / PhD Students / Post Docs Subscription: 50 EUR
Allied Health Professionals (AHP), PhD students and Post Docs may apply for membership at the discounted price which excludes access to the on-line and printed version of the Journal of Cystic Fibrosis.
This type of subscription is only available for AHP employed in Nursing, Nutrition/Dietetics, Pharmacy, Physiotherapy, Psychology or Social Work, PhD students and Post Docs.
For this type of subscription, please contact the ECFS at membership@ecfs.eu for a coupon code allowing the reduced rate.

<table>
<thead>
<tr>
<th>Special Membership Offers</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 3 years special rate</td>
<td>300 € instead of 360 € for a full membership until end 2018</td>
</tr>
<tr>
<td>• Registration + membership</td>
<td>Take your membership and register to the conference in one step</td>
</tr>
<tr>
<td>• Allied Health Professionals / PhD Students and Post Docs</td>
<td>50 € – Same benefits as the Full membership besides the subscription to the JCF (please apply to <a href="mailto:membership@ecfs.eu">membership@ecfs.eu</a> for reduction code)</td>
</tr>
</tbody>
</table>

10. ECFS Website

We invite our members to visit the ECFS website and encourage all to send us information and material to be shared with the CF community.
We have recently added a page dedicated to corporate grants, and count on your help to expand it.

Also, the page dedicated to EU funded projects provides links where more specific information can be found on the projects.

11. Upcoming Events

- ECFS Diagnostic Network Working Group Meeting – 11-13 February 2016 - London, UK,
12. Current references in Cystic Fibrosis

Please scroll down to next page
CF References

Adults & Adolescents

Backstrom-Eriksson L., Sorjonen K., Bergsten-Brgefors A., Hjelte L., Melin B. Anxiety and depression in adults with cystic fibrosis: a comparison between patients and the general population in Sweden and three other European countries BMC Pulmonary Medicine 2015; 15: ArtNo: 121

Diebska G., Mazurek H. Factors related to changes in the quality of life among Polish adolescents and adults with cystic fibrosis over a 1-year period Patient Preference and Adherence 2015; 9: 1763 - 1770


Jimenez DG., Codocoro RM., Garcia MG., Arias MM., Beltran MA., Romero RG., Costa CM., Olivas SMM., Quintana LP., Gutierrez SG., de Miguelans JMM., Cortina LS., Ponce ENC., Trabazo RL., Cruz FM., Martin JJD., Garcia CB. Vitamin D and chronic lung colonization in pediatric and young adults with cystic fibrosis Nutrition Hospitularia 2015; 32: 1629 - 1635


Kazmerski TM., Miller E., Abebe KZ., Matisko J., Schachner D., Spahr J. Patient Knowledge and Clinic Attendance in Adolescent Patients with Cystic Fibrosis Pediatric Allergy Immunology and Pulmonology 2015; 28: 107 - 111


Michl RK., Mues S., Mainz JG., Markert UR. Pregnancy and Cystic Fibrosis: An Overview Zeitschrift fur Geburtshilfe und Neonatologie 2015; 219: 170 - 175


Animal Model


Dennis EA., Coats MT., Griffin SE., Hale JY., Novak L., Briles DE., Crain MJ. The Effects of CFTR and Mucoid Phenotype on Susceptibility and Inmate Immune Responses in a Mouse Model of Pneumococcal Lung Disease PLoS One 2015; 10: e0140335

Fontes G., Ghislain J., Benterki I., Zarrourki B., Trudel D., Berthiaume Y., Poulton V. The Delta F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With Progressive Insulin Resistance and Decreased Functional beta-Cell Mass in Mice Diabetes 2015; 64: 4112 - 4122


Antimicrobials

Abdalla MY., Switzer BL., Goss CH., Aitken ML., Singh PK., Britigan BE. Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus Antimicrobial Agents and Chemotherapy 2015; 59: 4826 - 4834


Caceres LD., Marcos MC., Moreno RMG. Cystic Fibrosis and Piperacillin-tazobactam: Adverse Reactions Archives of Bronconeumologia 2015; 51: 664 - 665


Doh T., Hentschel J., Fischer N., Lehmann T., Markert UR., Boer K., Pfister W., Pletz MW., Guntinas Lichius O., Mainz JG. Reduced effect of intravenous antibiotic treatment on sinonasal markers in pulmonary inflammation Rhinology 2015; 53: 249 - 259


Ehsan Z., Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin Future Microbiology 2015; 10: 1901 - 1912


CFTR

Ahner A., Frizzell RA.

Aleksandrov LA., Jensen TJ., Cui LY., Kousouros JN., He LH., Aleksandrov AA., Riordan JR.
Thermal stability of purified and reconstituted CFTR in a locked open channel conformation Protein Expression and Purification 2015; 116: 159 - 166

Alves MG., Sa R., Jesus TT., Sousa M., Oliveira PF.
CFTR Regulation of Aquaporin-Mediated Water Transport: A Target in Male Fertility Current Drug Targets 2015; 16: 993 - 1006

Bahd CD., Hvorenc KL., Bomberger JM., Stanton BA., Hammock BD., Morisseau C., Madden DR.

Bellegue J., Bacchetta M., Lasa D., Aneogn, L., Chanson M., Nguyen TH.

Bergougoux N., A., Viart V., Miro J., Bommart S., Molinari G., des Georges M., Caustres M., Chiron R., Taulan-Cadars M.
Should diffuse bronchiectasis still be considered a CFTR-related disorder? Journal of Cystic Fibrosis 2015; 14: 646 - 653

Billet A., Jia YL., Jensen T., Riordan JR., Hanrahan JW.
Regulation of the cystic fibrosis transmembrane conductance regulator anion channel by tyrosine phosphorylation FASEB Journal 2015; 29: 3945 - 3953

Borowitz D.
CFTR, bicarbonate, and the pathophysiology of cystic fibrosis Pediatric Pulmonology 2015; 50:

Bose SJ., Scott-Ward TS., Cai ZW., Sheppard DN.
Exploiting species differences to understand the CFTR Cl- channel Biochemical Society Transactions 2015; 43: 975 - 982

Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent alpha-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors Organic & Biomolecular Chemistry 2015; 13: 10734 - 10744

Chang MC., Jan IS., Liang PC., Jeng YM., Yang CY., Tien YW., Wong JM., Chang YG.
Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment Journal of Cystic Fibrosis 2015; 14: 661 - 667

Chong PA., Farber PJ., Vernon RM., Hudson RP., Mittermaier AK., Forman-Kay JD.
Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization Journal of Biological Chemistry 2015; 290: 22862 - 22878

Clarke LA., Botelho HM., Sousa L., Fulcao AO., Amaral MD.
Transcriptome meta-analysis reveals common differential and global gene expression profiles in cystic fibrosis and other respiratory disorders and identifies CFTR regulators Genomics 2015; 106: 268 - 277

Corradi V., Vergani P., Tielemans DP.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) CLOSED AND OPEN STATE CHANNEL MODELS Journal of Biological Chemistry 2015; 290: 22891 - 22906

Cui GY., McCarty NA.
Murine and human CFTR exhibit different sensitivities to CFTR potentiators American Journal of Physiology-Lung Cellular and Molecular Physiology 2015; 309: L687 - L699

Dittrich NP., Kummer W., Claus W., Fronius M.
Luminal acetylcholine does not affect the activity of the CFTR in tracheal epithelia of pigs International Immunopharmacology 2015; 29: 166 - 172

Dong ZW., Chen J., Ruan YC., Zhou T., Chen Y., Chen YJ., Tsang LL., Chan HC., Peng YZ.
CFTR-regulated MAPK/NF-kappa B signaling in pulmonary inflammation in thermal inhalation injury Scientific Reports 2015; 5: ArtNo: 15946

Eckford PDW., Li CH., Bear CE.
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein JOVE-Journal of Visualized Experiments 2015; : 97:e52427

Farkkhi V., Rajrami B., Nemat R., McShane AJ., Rueckert F., Wells B., Yao XD.
Development of Structural Marker Peptides for Cystic Fibrosis Transmembrane Conductance Regulator in Cell Plasma Membrane by Reversed-Footprinting Mass Spectrometry Analytical Chemistry 2015; 87: 8603 - 8607

Gao Z., Su X.
CFTR regulates acute inflammatory responses in macrophages QJM-AN-International Journal of Medicine 2015; 108: 951 - 958

Goralski JL., Davis SD.
Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics Pediatric Pulmonology 2015; 50:

Gosalia N., Harris A.
Chromatin Dynamics in the Regulation of CFTR Expression Gene 2015; 6: 543 - 558

Hammad MM., Dunn HA., Walther C., Ferguson SSG.
Role of cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) in regulating the trafficking and signaling of corticotropin-releasing factor receptor 1 Cellular Signalling 2015; 27: 2120 - 2130

Jansson K., Venugopal J., Sanchez G., Magenheimer BS., Reif GA., Wallace DP., Calvet JP., Blanco G.
Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells Journal of Membrane Biology 2015; 248: 1145 - 1157

Kim Y., Anderson MO., Park J., Lee MG., Namkung W., Verkman AS.
Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 Inhibits CFTR Chloride Channel Gating by Competition with ATP Molecular Pharmacology 2015; 88: 689 - 696

Li K., Tang HP., Xu WX., Chen AJ., Shi QX., Sun ZD., Wang L.Y., Ni Y.
Antisera preparation and epitope mapping of a recombinant protein comprising three peptide fragments of the cystic fibrosis transmembrane conductance regulator Protein Expression and Purification 2015; 114: 23 - 29

Lopes-Pacheco M., Boinot C., Sabirzhanova I., Morales MM., Guggino WB., Cebotaru L.
Combination of Correctors Rescue Delta F508-CFTR by Reducing Its Association with Hsp40 and Hsp27 Journal of Biological Chemistry 2015; 290: 25636 - 25645

Micoud J., Chauvet S., Scheckenach KEL., Alfaidy N., Chanson, M., Benharouga M.
Involvement of the heterodimeric interface region of the nucleotide binding domain-2 (NBD2) in the CFTR quaternary structure and membrane stability Biochimica et Biophysica Acta-Molecular Cell Research 2015; 1853; 2420 - 2431

Molinski SV., Ahmadi S., Scott J., Sabirzhanova I., Morales MM., Guggino WB., Cebotaru L.
Combination of Correctors Rescue Delta F508-CFTR by Reducing Its Association with Hsp40 and Hsp27 Journal of Biological Chemistry 2015; 290: 25636 - 25645

Moon C., Zhang WQ., Sundaram N., Varlagadda S., Reddy VS., Arora K., Helmarth MA., Naren AP.
Pankow S., Bamberger C., Calzolari D., Martinez-Bartolome S., Lavalle-Adam M., Balch WE., Yates JR.
Delta F508 CFTR interactome remodelling promotes rescue of cystic fibrosis
*Nature* 2015; 528: 510

Peters W., Kusche-Vihrog K., Oberleithner H., Schillers H.
Cystic fibrosis transmembrane conductance regulator is involved in polyphenol-induced swelling of the endothelial glyocalyx
*Nanomedicine-Nanotechnology Biology and Medicine* 2015; 11: 1521 - 1530

Phuan PW., Veit G., Tan JA., Finkbeiner WE., Lukaes GL., Verkman AS.
Potentiators of Defective Daf-508-CFTR Gating that Do Not Interfere with Corrector Action
*Molecular Pharmacology* 2015; 88: 791 - 799

Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives
*European Journal of Medicinal Chemistry* 2015; 101: 236 - 244

Pollock NL., Rimlington TL., Ford RC.
Characterizing diverse orthologues of the cystic fibrosis transmembrane conductance regulator protein for structural studies
*Biochemical Society Transactions* 2015; 43: 894 - 900

Ramli NSK., Giribabu N., Muniandy S., Salleh N.
Testosterone regulates levels of cystic fibrosis transmembrane regulator, adenylyl cyclase, and cAMP in the seminal vesicles of orchidectomized rats
*Theriogenology* 2016; 85: 238 - 246

Roxo-Rosa M., Jacinto R., Sampaio P., Lopes SS.
The zebrafish Kupffer’s vesicle as a model system for the molecular mechanisms by which the lack of Polycystin-2 leads to stimulation of CFTR
*Biochimica et Biophysica Acta* 2015; 1848: 2942 - 2951

Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry
*Chembiochem* 2015; 16: 2017 - 2022

Sorum B., Czege D., Csanady L.
Click Chemistry
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry
*Chembiochem* 2015; 16: 2017 - 2022

Vitzthum C., Clauss WG., Fronius M.
Mechanosensitive activation of CFTR by increased cell volume and hydrostatic pressure but not shear stress
*Biochimica et Biophysica Acta* 2015; 1848: 2942 - 2951

Woodworth BA.
Resveratrol Ameliorates Abnormalities of Fluid and Electolyte Secretion in a Hypoxia-Induced Model of Acquired CFTR Deficiency
*Laryngoscope* 2015; 125:

Yang H., Ma TH.
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review
*Expert Opinion On Therapeutic Patents* 2015; 25: 991 - 1002

Chin M., Earlam K., Aaron SD.
Survival in Cystic Fibrosis: Trends, Clinical Factors, and Prediction Models
*Pediatric Allergy Immunology and Pulmonology* 2015; 28: 244 - 249

Diaconu R., Bozomitu L., Anton E., Popovici P., Anton C., Timofte D., Alin C., Moraru E.
Infectious and nutritional mechanisms in children with cystic fibrosis
*Archives of Biological Sciences* 2015; 67: 1063 - 1066

Er B., Koksal D., Kalyoncu U., Ozmen O., Emiraloglu N., Yalcin EG., Ergun E., Emri S.
Takayasu's arteritis as the aetiology of un resolved fever in an adult patient with cystic fibrosis
*Acta Clinica Belgica* 2015; 70: 295 - 298

Nie SA., Zhang HB., Mayer KML, Oppenheim FG., Little FF., Greenberg J., Uuer AZ., Walt DR.
Correlations of Salivary Biomarkers with Clinical Assessments in Patients with Cystic Fibrosis

Ong T., Ramsey BW.
Update in Cystic Fibrosis 2014
*American Journal of Respiratory and Critical Care Medicine* 2015; 192: 669 - 675

Ramsey KA., Schultz A., Stick SM.
Biomarkers in Paediatric Cystic Fibrosis Lung Disease
*Paediatric Respiratory Reviews* 2015; 16: 213 - 218

Sawicki GS., Goss CH.
Tackling the increasing complexity of CF care
*Pediatric Pulmonology* 2015; 50:

Shieh MB., Rivlin J., Gur M., Konopnicki M., Stein N., Tunney MM., Elborn JS., Downey DG., Johnston E., Shalomm H., Levy A.
Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis Outcomes
*Lung* 2015; 193: 1017 – 1021

**Diabetes**

Battezzati A., Bedogu G., Zazzaron L., Mari A., Battezzati PM., Alicandro G., Bertoli S., Colombi C.
Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients
*Journal of Clinical Endocrinology & Metabolism* 2015; 100: 2963 - 2971

Hayes D., Patel AV., Black SM., McCoy KS., Kirby S., Tobias JD., Mansour HML, Whilton BA.
Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation
*Journal of Thoracic and Cardiovascular Surgery* 2015; 150: 707 - 712

Lavie M., Fisher D., Vilozni D., Forschmidt R., Sarouk I., Kanety H., Moses D.
Glucose intolerance in cystic fibrosis as a determinant of pulmonary function and clinical status
*Diabetes Research and Clinical Practice* 2015; 110: 276 - 284

Megias MC., Albarraín OG.
Cystic fibrosis-related diabetes: a distinct condition
*Endocrinologia Y Nutricion* 2015; 62: 38 - 44

Megias MC., Albarraín OG., Vasco PG., Ferreiro AL., Carro LM.
Insulin resistance, beta-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis
*Endocrinologia y Nutricion* 2015; 62: 91 - 99

Megias MC., Vasco PG., Albarraín OG., Ferreiro AL., Carro LM.
Association of the relative change in weight and body mass index with lung function in teenagers and adults with cystic fibrosis: Influence of gender and diabetes
*Endocrinologia y Nutricion* 2015; 62: 422 - 429

Sheikh S., Putt ME., Forde KA., Rubenstein RC., Kelly A.
Elevation of One Hour Plasma Glucose During Oral Glucose Tolerance Testing
*Pediatric Pulmonology* 2015; 50: 963 - 969

**Clinical**

Baker AM., Rickert KA., Sawicki GS., Eakin MN.
CF RISE: Implementing a Clinic-Based Transition Program
*Pediatric Allergy Immunology and Pulmonology* 2015; 28: 250 - 254
Diagnosis


Matzeu G., O’Quigley C., McNamara E., Zuliani C., Fay C., Glennon T., Diamond M. An integrated sensing and wireless communications platform for sensing sodium in sweat Analytical Methods; 2016; 8: 64 - 71

McKone EF., Velentgas P., Swenson AJ., Goss CH. Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype Journal of Cystic Fibrosis 2015; 14: 580 - 586


Exercise


Armeniakon E., Perpati G., Dimopoulos S., Roditis P., Avdikou M., Barouchos N., Dionisopoulos V., Nanas S. Prolonged Oxygen Kinetics During Constant Workload Submaximal Exercise Is Associated With Disease Severity in Adult Subjects With Cystic Fibrosis Respiratory Care 2015; 60: 1164 - 1171


Kirkby SE., Hayes D., Parsons JP., Wisely CE., Kopp B., McRoy KS., Mastronarde JG. Eucapnic Voluntary Hyperventilation to Detect Exercise-Induced Bronchoconstriction in Cystic Fibrosis Lang 2015; 193: 733 - 738


Savi D., Simmonds N., Di Paolo M., Quattrucci S., Palange P., Banya W., Hopkinson NS., Bilton D. Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis BMC Pulmonary Medicine 2015; 15; ArNo: 151


Gastroenterology


Grime CJ., Greenaway C., Clarke S., Balfour-Lynn IM. Critical timing of gastrostomy insertion in a child with cystic fibrosis Paediatric Respiratory Reviews 2015; 16:


Gene Therapy


General Review

Nwokoro CEC. Highlights of the 28th North American Cystic Fibrosis Conference 2014 Paediatric Respiratory Reviews 2015; 16:

Simmonds NJ. Cystic Fibrosis Papers of the Year, 2013-2014 Paediatric Respiratory Reviews 2015; 16:

Genetics


Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis
*Genetics in Medicine* 2015; 17: 796 - 806

Cankaya T., Arikian-Ayyildiz Z., Bora E., Uzuner N., Ugenalp A.
Sequencing of the CFTR gene in selected Turkish patients with cystic fibrosis
*Minerva Pediatrica* 2015; 67: 407 - 411

Chang EH., Zabner J.
Precision Genomic Medicine in Cystic Fibrosis
*CTS-Clinical and Translational Science* 2015; 8: 606 - 610

Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis
*Nature Communications* 2015; 6: ArNo: 8382

Elce A., Di Lullo AM., Amato F., Liguori R., Zarrilli F., Castaldo G.
Cystic fibrosis, molecular genetics for all life
*Journal of Pediatric and Neonatal Individualized Medicine* 2015; 4: 2:e004252

Giorgi G., Casarin A., Trevisson E., Dona M., Cassina M., Graziano C., Pici L., Clementi M., Salviati L.
Validation of CFTR intronic variants identified during cystic fibrosis population screening by a minigene splicing assay
*Clinical Chemistry and Laboratory Medicine* 2015; 53: 1719 - 1723

Nefzi M., Fredj SH., Tebib N., Barsaoui S., Boussetta K., Siala H., Messaoud T.
Contribution of M470V variant to cystic fibrosis: First study in CF and normal Tunisian population
*Pathologie Biologie* 2015; 63: 169 - 174

Oueslati S., Fredj SH., Dakhlaoui B., Othmani R., Siala H., Messaoud T.
Association of TGFB1-500C/T polymorphism gene with clinical variability in cystic fibrosis patients: A case-control study
*Pathologie Biologie* 2015; 63: 175 - 178

Simakova T., Kondratyeva E., Avakian L., Bragin A., Zaytseva M., Pavlov A.
*Gene* 2016; 575: 567 - 569

Singh M., Rebobrada C., Bernholz J., Sharma N.
Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments
*Respirology* 2015; 20: 1172 - 1181

Sirimongpong N., Yang Z.
EpiGenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease Current Drug Targets 2015; 16: 976 - 987

Yang XJ., Sun QP., Yuan P., Liang H., Wu X., Lai I.H., Zhang Y.
Novel mutations and polymorphisms in the CFTR gene associated with three subtypes of congenital absence of vas deferens
*Fertility and Sterility* 2015; 104: 1268 - 1277

Sanders DB., Fink A., Mayer-Hamblett N., Schechter MS., Sawicki GS., Rosenfeld M., Flume PA., Morgan WJ.
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years
*Journal of Pediatrics* 2015; 167: 1081 - 1086

Sands D., Mielus M., Umlawska W., Lipowicz A., Oralewska B., Walkowiak J.
Evaluation of factors related to bone disease in Polish children and adolescents with cystic fibrosis
*Advances in Medical Sciences* 2015; 60: 315 - 320

Zhang ZM., Shoff SM., Lai HCJ.
Comparing the Use of Centers for Disease Control and Prevention and World Health Organization Growth Charts in Children with Cystic Fibrosis through 2 Years of Age
*Journal of Pediatrics* 2015; 167: 1089 – 1095

**Immunology & Inflammation**

Antus B., Drozdovszy O., Barta L., Kelemen K.
Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis
*Lung* 2015; 193: 597 - 604

Chmiel JF., Konstan MW., Accurso FJ., Lynp J., Mayer-Hamblett N., VanDevanter DR., Rose LM., Ramsey BW.
Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis
*Journal of Cystic Fibrosis* 2015; 14: 720 - 726

Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth
*European Respiratory Journal* 2015; 46: 1033 - 1045

Johansen HK., Gotzsche PC.
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
*Cochrane Database of Systematic Reviews* 2015; : 8:CD001399

Vaccine coverage in CF children: A French multicenter study
*Journal of Cystic Fibrosis* 2015; 14: 615 - 620

Nichols DP., Chmiel JF.
Inflammation and its genesis in cystic fibrosis
*Pediatric Pulmonology* 2015; 50:

Oglesby IK., Vencken SF., Agrawal K., Molloy K., Higgins G., McNally P., McElvaney NG., Mall MA., Greene CM.
miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production
*European Respiratory Journal* 2015; 46: 1350 - 1360

Ooi CY., Pang T., Leach ST., Katz T., Day AS., Jaffe A.
Fecal Human beta-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?
*Digestive Diseases and Sciences* 2015; 60: 2946 - 2952

Sass LA., Hair PS., Perkins AM., Shah TA., Krishna NK., Cunnion KM.
Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease

**Liver Disease**

Canas T., Macia A., Munoz-Codoco RA., Fontanilla T., Gonzalez-Rios P., Miralles M., Gomez-Mardones G.
Hepatic and Spleenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis
*Biomed Research International* 2015; : ArNo: 517369
Microbiology

Abdul Wahab A., Taj-Aldeen SJ., Ibrahim EB., Talaq E., Abu-Madli M., Fotedar R.
Discrepancy in MALDI-TOF MS identification of uncommon Gram-negative bacteria from lower respiratory secretions in patients with cystic fibrosis

Infection and Drug Resistance 2015; 8: 83 - 88

Ali H., Orchard C., Mariuves M., Scott S., Alshafi K., Bilton D., Simmonds N.
Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis

European Respiratory Journal 2015; 46: 1046 - 1054

Barre HL., Halliday N., Camara M., Barrett DA., Williams P., Forrester DL., Simms R., Smyth AR., Honeybourne D., Whitehouse JL., Nash EF., Dewar J., Clayton A., Know AJ., Fogarty AW.
Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis

European Respiratory Journal 2015; 46: 1046 - 1054

Bartke C., Nandakumar S., Derlich L., Macey J., Buí S., Fayon M., Crouzet M., Garbay B., Vilain S., Costaglioli P.
Expression of Pseudomonas aeruginosa genes directly from spuTa of cystic fibrosis patients

Letters in Applied Microbiology 2015; 61: 423 - 428

Exploring the expression of Pseudomonas aeruginosa genes directly from infected human bronchial epithelial cells

European Respiratory Journal 2015; 46: 1046 - 1054

Casciaro R., Naselli A., Cresta F., Ros M., Castagnola E., Minicucci A.
Microbiome 2015; 3: ArtNo: UNSP 12

Carmody LA., Zhao JC., Kalikin LM., LeBar W., Simon RH., Venkataraman A., Schmidt TM., Abdó Z., Schloss PD., LiPuma JJ.
The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation

Microbiome 2015; 3: ArNo: UNSP 12

Casiricco R., Naselli A., Cresta F., Ros M., Castagnola E., Minicucci A.
Role of neutalized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature

Journal of Chemotherapy 2015; 27: 307 - 311

Caverly LJ., Zhao JC., LiPuma JJ.
Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection

Pediatric Pulmonology 2015; 50:

Collie D., Glendinning L., Govan J., Wright S., Thornton E., Tennant P., Doherty C., McLachlan G.
Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium


Coolen N., Morand P., Martin C., Hubert D., Kanaan R., Chapron J., Honore I., Dusser D., Audureau E., Veiziris N., Burgel PR.
Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin

Journal of Cystic Fibrosis 2015; 14: 594 - 599

Coutinho CP., Barreto C., Pereira L., Lito L., Cristino JM., Sa-Correia I.
Incidence of Burkholderia contaminans at a cystic fibrosis centre with an unusually high representation of Burkholderia cepacia during 15 years of epidemiological surveillance

Journal of Medical Microbiology 2015; 64: 927 - 935

Phenotypic characterization of an international Pseudomonas aeruginosa strain panel: strains from cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains

Microbiology-SGM 2015; 161: 1961 - 1977

Dualethae N., Das M., Cammisano M., Chen H., Singh S., Kooi C., Leigh R., Beaudoin T., Rousseau S., Lands I.C.
Rhinovirus Load Is High despite Preserved Interferon-beta Response in Cystic Fibrosis Bronchial Epithelial Cells


A causal link exists between male gender and a high incidence of Pseudomonas aeruginosa colonisation in the lung of CF patients

Bmc Infectious Diseases 2015; 15: ArNo: 583

Activation of Human Toll-like Receptor 4 (TLR4) by Hypocystylated Lipo polysaccharide from a Clinical Isolate of Burkholderia cepacia

Journal of Biological Chemistry 2015; 290: 21305 - 21319

Duong J., Booth SC., McCartney NK., Rabin H.R., Parkins MD., Storey DG.
Phenotypic and Genotypic Comparisons of Epidemic and Non-Epidemic Pseudomonas aeruginosa Strains from Individuals with Cystic Fibrosis


Ferreira AG., Leao RS., Carvalho-Assaf APD., Da Silva EADR., Firmida MD., Folescu TW., Paixao V.A., Santana MA., Silva FADE., Barth AL., Marques EA.
Low-level resistance and clonal diversity of Pseudomonas aeruginosa among chronically colonized cystic fibrosis patients

APMIS 2015; 123: 1069 - 1077

Floto RA., Olivier KN., Saiman L., Daley CL., Herrmann JL., Nick JA., Noone PG., Bilton D., Corriss P., Gibson RL., Hempstead SE., Koetz PMIS.
Burkholderia cenocepacia: clinical course in cystic fibrosis patients

Thorax 2016; 71: 88 - 90

Folescu TW., da Costa CH., Cohen RWF., Neto OCD., Albano RM., Ferreira AG., Carvalho MA., Corri Cora E., Roldan A., Barreto C., Pereira L., Cristino JM., Sa-Correia I.
Burkholderia contaminans at a cystic fibrosis centre with an unusually high representation of Burkholderia cepacia during 15 years of epidemiological surveillance

Journal of Medical Microbiology 2015; 64: 927 - 935

BURKHOLDERIA CONTAMINANS AT A CYSTIC FIBROSIS CENTRE WITH AN UNUSUALLY HIGH REPRESENTATION OF BURKHOLDERIA CEPA

Journal of Cystic Fibrosis 2015; 14: 594 - 599

The effects of nickel(II) complexes with imidazole derivatives on pyocyanin and pyoverdine production by Pseudomonas aeruginosa strains isolated from cystic fibrosis

Acta Biochimica Polonica 2015; 62: 739 - 745

High variability in quorum quenching and growth inhibition by furanone C-30 in Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients

Pathogens and Disease 2015; 73: 6:UNSP f040
Pseudomonas aeruginosa inhibits the growth of Scedosporium

Garcia-Lara B., Saucedo-Mora MA., Roldan-Sanchez JA., Perez-Eretza B., Ramasamy M., Lee J., Coria-Jimenez R., Tapia M., Varela-Guerrero V., Garcia-Contreras R.

Inhibition of quorum-sensing-dependent virulence factors and biofilm formation of clinical and environmental Pseudomonas aeruginosa strains by ZnO nanoparticles

Letters in Applied Microbiology 2015; 61: 299 - 305

Geake JB., Reid DW., Currie BJ., Bell SC.

An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis

BMC Pulmonary Medicine 2015; 15: ArtNo: 116

Ghoul M., West SA., Johansen HK., Molin S., Harrison OB., Maiden MCJ., Jelsbak L., Bruce JB., Griffin AS.

Bacteriocin-mediated competition in cystic fibrosis lung infections

Proceedings of the Royal Society B-Biological Sciences 2015; 282: 146 - 153

Gi M., Lee KM., Kim SC., Yoon JH., Yoon SS., Choi JY.

A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus

Scientific Reports 2015; 5: ArtNo: 14644

Giles-Hillet A., Shoosey D., Polacheck L., Korem M., Kerem E., Cohen-Cymberknoh M.

Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis

Pediatric Pulmonology 2015; 50: 1082 - 1089

Goeman EE., Shivam A., Downton TD., Glaviney AR.

Bacteremic Inquilinus limosus empyema in an Australian lung transplant patient with cystic fibrosis

Journal of Heart and Lung Transplantation 2015; 34: 1220 - 1223

Goeminne PC., Nawrot TS., De Bock K., Nemery B., Dupont LJ.

Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A case-control analysis

Journal of Cystic Fibrosis 2015; 14: 741 - 747

Guglielmetti L., Mogari F., Lopes A., Raskine L., Cambau E.

Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists' point of view

Future Microbiology 2015; 10: 1467 - 1483

Hoen AG., Li J., Moultan LA., O'Toole GA., Housman ML., Koestler HC., Karagas MR., Madan JC.

Associations between Gut Microbial Colonization in Early Life and Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists' point of view

Future Microbiology 2015; 10: 1467 - 1483

Hoen AG., Li J., Moultan LA., O'Toole GA., Housman ML., Koestler HC., Karagas MR., Madan JC.

Associations between Gut Microbial Colonization in Early Life and Respiratory Outcomes in Cystic Fibrosis


Horesh E., Colin AA., Casiano R., Wester ST.

An atypical presentation of sinus mucopyocele in a pediatric cystic fibrosis patient

Clinical Ophthalmology 2015; 9: 821 - 824

Jat KR., Walia DK., Kharwia A.

Ant-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Er J, Dijkgraaf MG., Groot KJ., Huijbregts A., van Dijk JP., van Boxtel D., van der Waal CG., van den Berg M., Willems J., Koetsier MCJ., Jelsbak L., Bruce JB., Griffin AS.

Bacteriocin-mediated competition in cystic fibrosis lung infections

Proceedings of the Royal Society B-Biological Sciences 2015; 282: 146 - 153

Koitschev A., Khan GM., Mora MA., Roldan MCJ., Jelsbak L., Bruce JB., Gough M., West SA., Johansen HK., Molin S., Taccetti G., Johansen HK.

Role of small colony variants in persistence of Pseudomonas aeruginosa in airway mucus

Pediatric Pulmonology 2015; 50: 1082 - 1089


Cohort Study of Airway Mycobiome in Adult Cystic Fibrosis Patients: Differences in Community Structure between Fungi and Bacteria Reveal Predominance of Transient Fungal Elements

Journal of Clinical Microbiology 2015; 53: 2900 - 2907

Lemney W.

Pseudomonas aeruginosa in cystic fibrosis is potentially serious, and more than merely a marker for disease severity

Paediatric Respiratory Reviews 2015; 16

Lim M., Viles J., How KY., Lee SK., Yong D., Lee BK., Yin WF., Chan KG.

Complete genome sequencing of Pandoraea promenens RB38 and Molecular Characterization of its N-acetyl homoserine lactone synthase gene pnp

PEERJ 2015; 3: ArNo: e1225

Linnane B., Kearse L., O'Connell NH., Fenton J., Kiernan MG., Dunne CP.

A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosa

BMC Pulmonary Medicine 2015; 15: ArNo: 114

Lopez-Medina E., Fan D., Coughlin LA., Ho EX., Lamont IL., Reimann C., Hooper LV., Koh AY.

Candida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis

PLoS Pathogens 2015; 11: 8:e1005129

Magon NJ., Turner R., Garey RB., Hampton MB., Sly PD., Kettle AJ.

Oxidation of calpain by hypochlorous acid prevents chelation of essential metal ions and allows bacterial growth: Relevance to infections in cystic fibrosis

Free Radical Biology and Medicine 2015; 86: 133 - 144

Mainz JG., Gerber A., Arnold C., Baumann J., Baumann L., Koltschev A.

Rhinosinusitis in cystic fibrosis

HNO 2015; 63: 809 - 818

Malone JG.

Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs

Infection and Drug Resistance 2015; 8: 237 - 247

Marvig RL., Dolce D., Sommer LM., Petersen B., Ciofu O., Campaña S., Molin S., Taccetti G., Johansen HK.

Impact of Sustained Eradication of New Pseudomonas aeruginosa Infections on Long-term Outcomes in Cystic Fibrosis

Clinical Infections Diseases 2015; 61: 707 - 713

Maturu VN., Agarwal R.

Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis

Clinical and Experimental Allergy 2015; 45: 1765 - 1778

Mayer NO., Mirot M., Mirkovic B., Murray MA., Lavelle GM., Molloy K., Malone JG.

The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway

American Journal of Respiratory and Critical Care Medicine 2015; 192: 1314 - 1324

Moore JE., McPherson J., McElvaney NO., Tunney MM., Muhelebach MS., Devery R., Greene CM., McElvaney NG.

How reliable are cough swabs for the detection of Pseudomonas aeruginosa in adult patients with cystic fibrosis?

British Journal of Biomedical Science 2015; 72: 206
Murphy MP, Caraher E. Residence in biofilms allows Burkholderia cepacia complex (Bcc) bacteria to evade the antimicrobial activities of neutrophil-like hIL60 cells. *Pathogens and Disease* 2015; 73: 8: UNSP iv069


Periasamy S, Nair HAS, Lee KWK, Ong J, Goh JQJ, Kjelleberg S, Rice SA. Pseudomonas aeruginosa PA01 exopolsaccharides are important for mixed species biofilm community development and stress tolerance. *Frontiers in Microbiology* 2015; 6: ArNo: 851


Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. *Cochrane Database of Systematic Reviews* 2015; : 11:CD009661

Webster TA, Sismaet HJ, Sattler AF, Goluch ED. Improved monitoring of P. aeruginosa on agar plates. *Analytical Methods* 2015; 7: 7150 - 7155

**Nutrition**


Connett GJ, Pike KC. Nutritional outcomes in cystic fibrosis - are we doing enough? *Paediatric Respiratory Reviews* 2015; 16:

Cottam ST, Connett GJ. Routine use of daily oral vitamin K to treat infants with cystic fibrosis. *Paediatric Respiratory Reviews* 2015; 16:


Sirimpong N., Yang Z., Bioactive Food Components as Dietary Intervention for Cystic Fibrosis Current Target Drugs 2015; 16: 988 - 992


Oral Aspects


Physiotherapy


Forton J., Induced sputum in young healthy children with cystic fibrosis Paediatric Respiratory Reviews 2015; 16: 4


Hoo ZH., Daniels T., Wildman MJ., Teare MD., Bradley JM., Airway clearance techniques used by people with cystic fibrosis in the UK Physiotherapy 2015; 101: 340 - 348


Psychosocial

Aaron SD., Stephenson AL., Cameron DW., Whitmore GA., A statistical model to predict one-year risk of death in patients with cystic fibrosis Journal of Clinical Epidemiology 2015; 68: 1336 - 1345

Abott J., Morton AM., Hurley MA., Conway SP., Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis BMJ Open 2015; 5: e007418


Duff AJA., Depression in cystic fibrosis; Implications of The International Depression/Axiety Epidemiological Study (TIDES) in cystic fibrosis Paediatric Respiratory Reviews 2015; 16:


Ewuruke E., Zeng QYL., Winterstein AG., Clinical and Sociodemographic Factors Associated With Attention-Deficit/Hyperactivity Disorder in Patients With Cystic Fibrosis Psychosomatics 2015; 56: 495 - 503

Forte GC., Barni GC., Perin C., Casarotto FC., Fagondes SC., Dalcin PDR., Relationship Between Clinical Variables and Health-Related Quality of Life in Young Adult Subjects With Cystic Fibrosis Respiratory Care 2015; 60: 1459 - 1468

Goldbeck L., Fedika A., Herle M., Quittnier AL., Cochrane corner: psychological interventions for individuals with cystic fibrosis and their families Thorax 2015; 70: 1089 - 1091


Ioannou L., Delatycki MB., Massie J., Hodgson J., Lewis S., “Suddenly Having two Positive People who are Carriers is a Whole New Thing” - Experiences of Couples Both Identified as Carriers of Cystic Fibrosis Through a Population-Based Carrier Screening Program in Australia Journal of Genetic Counseling 2015; 24: 987 - 1000


Moraru E., Diaconu R., Anton E., Bozomitu L., Anton MC., Understanding the relevance of pain, depression and anxiety-like manifestations in the management of cystic fibrosis Archives of Biological Sciences 2015; 67: 1031 - 1038


Validity Testing
Keller F., Kernen Y., Ranganathan SC., Hafen GM.

O., Chapron J., Honore I., Kanaan R., Legmann Dupont C., Gouya H., Panzo R., Hubert D., Correas JM., Agrario L.,
Laryngoscope 2015; 125: 2398

Stoltz DA.

Launspach JL., Horan RA., Kao SC., Chaloner K., M
diwakar A., Adam RJ., Michalski AS., Tamegnon MM., Fischer AJ.,
Pulmonology 2015; 50: 863 - 868

Morgan K., Osterling K., Gilbert R., Dechman G.

Morgan KA., Ranganathan SC., Gallgell CL., Turkovic L., Park J., Skoric B., Stick SM., Syl PD., Hall GL.

Pittman JE.


Ramsey KA., Ranganathan SC., Park J., Skoric B., Stick SM., Syl PD., Hall GL.

Impact of lung disease on respiratory impedance in young children with cystic fibrosis European Respiratory Journal 2015; 46: 672 - 631

Simpson SJ., Ranganathan S., Park J., Turkovic L., Robins-Browne RM., Skoric B., Ramsey KA., Roenow T., Banton GL., Berry L., Stick SM., Hall GL.

Progressive ventilation inhomogeneity in infants with cystic fibrosis pulmonary exacerbation European Respiratory Journal 2015; 46: 1680 - 1690


Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbation European Respiratory Journal 2015; 46: 1055 - 1064

Thompson V., Mayer-Hamblett N., Kloster M., Bilton D., Flume PA.

Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study Journal of Cystic Fibrosis 2015; 14: 632 - 638

VanDevanter DR., Pasta DJ., Konstan MW.

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis Journal of Cystic Fibrosis 2015; 14: 763 - 769

Veronezi J., Carvalho AP., Ricachiewsky C., Hoffmann A., Kobayashi DY., Pitcher OB., Silva FAAE, Martinez D.

Sleep-disordered breathing in patients with cystic fibrosis Jornal Brasileiro de Pneumologia 2015; 41: 351 - 357
Radiology

Carpio C., Albi G., Rayon-Alejo JC., Alvarez-Sala R., Giron R., Prados C., Caballero P.
Changes in structural lung disease in cystic fibrosis children over 4 years as evaluated by high-resolution computed tomography
European Radiology 2015; 25: 3377 - 3359

Cassery P., Harrison M., O’Connell O., O’Donovan N., Plant BJ., O’Sullivan P.
Nasal endoscopy and paranasal sinus computerised tomography (CT) findings in an Irish cystic fibrosis adult patient group
European Archives of Oto-Rhino-Laryngology 2015; 272: 3353 - 3359

Journal of Pediatrics 2015; 167: 862

Comparison Between Magnetic Resonance Imaging and Computed Tomography of the Lung in Patients With Cystic Fibrosis With Regard to Clinical, Laboratory, and Pulmonary Functional Parameters
Investigative Radiology 2015; 50: 743 - 742

Walkup LJ., Woods JC.
Advances in Imaging Cystic Fibrosis Lung Disease
Pediatric Allergy Immunology and Pulmonology 2015; 28: 220 - 229

Screening

Domíngos MT., Magdalena NIR., Cat MNL., Watanabe AM., Rosario NA.
Sweat conductivity and coulometric quantitative test in neonatal cystic fibrosis screening
Journal of Pediatria 2015; 91: 590 - 595

Gonska T., Ratjen F.
Newborn screening for cystic fibrosis

Grimaldi C., Bremett F., Berloz-Baudoin M., Brouard J., Corvol H., Couderc L., Ermund A., Meiss LN., Gustafsson JK., Hansson GC.
Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus
European Archives of Oto-Rhino-Laryngology 2015; 272: 3353 - 3359

Walkup LJ., Woods JC.
Advances in Imaging Cystic Fibrosis Lung Disease
Pediatric Allergy Immunology and Pulmonology 2015; 28: 220 - 229

Guglani L., Stabel D., Weiner DJ.
False-Positive and False-Negative Sweat Tests: Systematic Review of the Evidence
Pediatric Allergy Immunology and Pulmonology 2015; 28: 198 - 211

Loukas YL., Thodi G., Molou E., Georgiou V., Dotsikas Y., Schulpis KH.
Clinical diagnostic Next-Generation sequencing: The case of CFTR carrier screening
Scandinavian Journal of Clinical & Laboratory Investigation 2015; 75: 374 - 381

Ooi CY., Ratjen F., Gonska T.
Re: Stratifying Cystic Fibrosis Susceptibility in Newborn Screen Infants with Equivocal Sweat Chloride Levels Response
Pediatrics 2015; 136: E1489 - E1491

Changing incidence of cystic fibrosis in Wisconsin, USA
Pediatric Pulmonology 2015; 50: 1065 - 1072

Salinas DB., Sonnay PR., Azen C., Young S., Raraigh KS., Keens TG., Kharrazi M.
Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants
Journal of Cystic Fibrosis 2015; 14: 714 – 719

Therapy

Agent P., Parrott H.
Inhaled therapy in cystic fibrosis: agents, devices and regimens
Breathe 2015; 11: 111 - 118

Amaral MD., Balch WE.
Hallmarks of therapeutic management of the cystic fibrosis functional landscape
Journal of Cystic Fibrosis 2015; 14: 687 - 699

Azini A.
“Cystic fibrotics could survive cholera, choleraics could survive cystic fibrosis”; hypothesis that explores new horizons in treatment of cystic fibrosis
Medical Hypotheses 2015; 85: 715 - 717

Bangel-Ruland N., Tomczak K., Weber WM.
Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Current Drug Targets 2015; 16: 951 - 957

Bin-Hasan S., Ratjen F.
Tiotropium bromide for cystic fibrosis

Brodie M., Haq L., Roberts K., Elborn JS.
Targeted therapies to improve CFTR function in cystic fibrosis
Genome Medicine 2015; 7: ArtNo: 101

Bucki R., Cruz K., Pogoda K., Eggert A., Chak LK., Ferrin M., Imbesi G., Hadjiiliadis D., Janney PA.
Enhancement of Pulzyme activity in puerperal sputum by combination with poly-aspartic acid or gelsolin
Journal of Cystic Fibrosis 2015; 14: 587 - 593

Devereux G., Fraser-Pitt D., Robertson J., Devlin E., Mercer D., O’Neil D.
Cysteamin as a Future Intervention in Cystic Fibrosis against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucocleative Potential in Sputum EbioMedicine 2015; 2: 1507 - 1512

Ermund A., Meiss LN., Gustafsson JK., Hansson GC.
Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus

Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor
American Journal of Respiratory and Critical Care Medicine 2015; 192: 1252 - 1255

Graesemann H., Gonska T., Avolio J., Tullis E., Wilcox P., Freitag A., Thomeer J., Ratjen F.
Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis
Journal of Cystic Fibrosis 2015; 14: 727 - 732

Green HD., Barry PJ., Jones AM.
Anabolic agent use in adults with cystic fibrosis
Paediatric Respiratory Reviews 2015; 16: 717

Guglani L.
Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis
Indian Journal of Pediatrics 2015; 82: 727 - 736

Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?
Current Drug Targets 2015; 16: 958 - 964
Wilcock MJ., Ruddick A., Gyi KM., Hodson ME.
Renal diseases in adults with cystic fibrosis: a 40 year single centre experience
Journal of Nephrology 2015; 28: 585 - 591